The Immunogenicity and Safety of Oral Rotavirus Vaccine (Vero Cell)
Phase 2
Recruiting
- Conditions
- Rotavirus Gastroenteritis
- Interventions
- Biological: Oral hexavalent reassortant rotavirus attenuated live vaccineBiological: Oral pentavalent reassortant rotavirus attenuated live vaccine (controlled)
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06967272
- Locations
- 🇨🇳
Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China
Tolerability, Safety, and Immunogenicity of Oral Rotavirus Vaccine(Vero Cell) .
Phase 1
Active, not recruiting
- Conditions
- Rotavirus Gastroenteritis
- Interventions
- Biological: Oral hexavalent reassortant rotavirus attenuated live vaccineBiological: Placebo
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06950645
- Locations
- 🇨🇳
Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
Phase 1
Not yet recruiting
- Conditions
- Tetanus
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 255
- Registration Number
- NCT06939777
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Clinical Trial of PCV24 in Infants Aged 2-23 Months
Phase 1
Not yet recruiting
- Conditions
- Pneumococcal Infectious Disease
- Interventions
- Biological: Sinovac PCV24Biological: Prevnar®
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06800261
- Locations
- 🇨🇳
Shandong Provincial Center for Disease Control and Prevention, Jinan, Shandong, China
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
Phase 3
Recruiting
- Conditions
- Pneumococcal Infectious Disease
- Interventions
- Biological: Sinovac PCV13Biological: Prevnar®
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 3080
- Registration Number
- NCT06617715
- Locations
- 🇨🇳
Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China
Clinical Trial of PCV24 in Children Aged 2-17 Years
Phase 1
Recruiting
- Conditions
- Pneumococcal Infectious Disease
- Interventions
- Biological: Sinovac PCV24 formulation 1Biological: Sinovac PCV24 formulation 2Biological: Prevenar13®
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 114
- Registration Number
- NCT06550830
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing, Jiangsu, China
Clinical Trial of PCV24 in Adults
Phase 1
Completed
- Conditions
- Pneumococcal Infectious Disease
- Interventions
- Biological: Sinovac PCV24 formulation 1Biological: PlaceboBiological: Sinovac PCV24 formulation 2Biological: Pneumovax®
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 170
- Registration Number
- NCT06474377
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China
Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population
Phase 3
Completed
- Conditions
- Tetanus
- Interventions
- Biological: Investigational tetanus vaccine, adsorbedBiological: Control tetanus vaccine, adsorbed
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 1260
- Registration Number
- NCT06049940
- Locations
- 🇨🇳
Liangyuan District Center for Disease Control and Prevention, Shangqiu, Henan, China
SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19
Phase 1
Recruiting
- Conditions
- COVID-19
- Interventions
- Drug: SA55 InjectionOther: Placebo for SA55 injection
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06050460
- Locations
- 🇨🇳
Beijing Ditan Hospital Capital Medical University, Beijing, China
SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
Phase 1
Recruiting
- Conditions
- COVID-19
- Interventions
- Drug: SA55 nasal spray
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Sinovac Life Sciences Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06048393
- Locations
- 🇨🇳
Beijing Ditan Hospital Capital Medical University, Beijing, Chaoyang, China
© Copyright 2025. All Rights Reserved by MedPath